IGLVIVOR22-2

Across TCGA pan-cancer cohorts, IGLVIVOR22-2 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of IGLVIVOR22-2’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where IGLVIVOR22-2 RNA is repressed in tumor relative to normal tissue. In most cancer types IGLVIVOR22-2 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

THCA, KIRC, and LIHC are the cancer types where IGLVIVOR22-2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IGLVIVOR22-2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.088	<.001	4	view →
KIRC	Female	All	+0.105	.007	3	view →
LIHC	All	All	+0.028	.027	3	view →
KICH	Male	II,III,IV	+0.213	.004	2	view →
LUSC	All	All	+0.141	.005	2	view →
HNSC	All	III,IV	+0.082	.025	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

IGLVIVOR22-2–THCA

Open the THCA breakdown →